Clinical trials
Schizophrenia clinical trials
Below are recruiting schizophrenia clinical trials, each written for real people, not researchers. We’re tracking 306 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05036590Recruiting
Testing a family support program for first-episode psychosis
This study checks whether a structured family intervention helps caregivers support a person with schizophrenia or a first psychotic episode. You may be asked to take part in a step-by-step program and answer questions to see if it works better than usual care.
BronAges 18 years+ - NCT04987229Enrolling by invitationPhase 3
Kid’s long-term safety follow-up for OLZ and SAM treatment
This study checks how safe a kid’s ongoing treatment is over a longer period. It is mainly for children who already finished a related study and may benefit from continuing the same medicines.
Dothan, AlabamaAges 10–17 - NCT04940663Recruiting
Study brain and feelings in loneliness and social isolation
This study looks at how the brain and behavior relate to loneliness and feeling socially isolated in people with serious mental health conditions. It may help researchers understand what drives loneliness and how it could be addressed in the future.
Charlestown, MassachusettsAges 18–55 - NCT04798131Recruiting
Brain-scan training to reduce medication-resistant voices
This study uses brain scans (MRI) and real-time feedback to help train the brain to reduce frequent, distressing auditory hallucinations (hearing voices) in people with schizophrenia. If you qualify, you may try a structured neurofeedback program while researchers track changes in your symptoms.
LilleAges 18–60 - NCT04580134RecruitingPhase 4
Clozapine study for people with a specific schizophrenia or bipolar type
This trial tests whether clozapine works better for people whose illness fits a specific “biotype-1” pattern. It may help reduce ongoing symptoms, but it also requires close safety monitoring.
Hartford, ConnecticutAges 18–60 - NCT04478838RecruitingPhase 4
Alternate-day antipsychotic dosing for schizophrenia
This trial looks at whether taking an antipsychotic every other day can keep symptoms controlled in adults with schizophrenia or another psychotic disorder. It may help some people avoid daily dosing, but it requires specific medication stability and screening checks.
Toronto, OntarioAges 18 years+ - NCT04323566Enrolling by invitationPhase 2
Rituximab for OCD or psychosis linked to immune inflammation
This trial tests rituximab (an immune system medicine) to see if it can reduce OCD symptoms and/or psychosis when there are signs the immune system may be involved. You may be considered if other standard psychiatric treatments have not helped enough and your illness seems relatively recent with possible inflammation clues.
UppsalaAges 18–55 - NCT04370730Recruiting
Study brain and symptoms in youth with early psychosis
This study looks at how psychosis symptoms and development change over time in children and teens. It may help doctors better understand different patterns of illness and how to support young people with these disorders.
GentillyAges 7–20 - NCT04237155Recruiting
French memory and attention task for schizophrenia or controls
This study tests how people with schizophrenia and healthy volunteers track sources of information using a French computer task. It may help researchers better understand memory and thinking differences that could guide future support and treatments.
BronAges 18–45 - NCT03971487RecruitingPhase 1/Phase 2
Ocrelizumab for psychosis linked to an overactive immune system
This Phase 1/2 study tests ocrelizumab, a medicine that affects parts of the immune system, to see if it can improve psychosis symptoms in people with schizophrenia-spectrum disorders. It’s mainly for younger adults with ongoing psychosis and evidence that the symptoms began early in life, with certain infection/vaccine safety requirements.
Houston, TexasAges 18–35 - NCT03970005Enrolling by invitation
Step-based program for teens with early signs of psychosis
This trial tests a staged (“step-based”) mental health program for people ages 12–25 who have early warning signs that could develop into psychosis. It may help by targeting symptoms early and reducing the chance of worsening over time.
Columbus, OhioAges 12–25 - NCT03217110Recruiting
Brain stimulation study for thinking and control
This trial tests whether stimulating the cerebellum (a part of the brain involved in coordination and learning) can improve “cognitive control,” or the ability to focus and manage thoughts. You may be able to join if you have a diagnosis they are specifically enrolling for and you can safely complete the stimulation and study procedures.
Iowa City, IowaAges 18–90 - NCT02916810Recruiting
TMS for persistent auditory hallucinations using a new setup
This study tests a specific brain stimulation approach (TMS) to help reduce auditory hallucinations in adults with schizophrenia who have not improved enough with medications. It may help by changing how the brain regions involved in hearing voices are stimulated.
Houston, TexasAges 18–50 - NCT02878408Recruiting
Study of immune and genetics factors in bipolar or schizophrenia
This study looks at how the immune system, genetics, inflammation, and past exposures may relate to bipolar disorder or schizophrenia. It may help researchers understand the cause and find better ways to support people with these conditions.
Créteil, FranceAges 16 years+ - NCT02670447Recruiting
Checking new support for a first psychosis, no prior medication
This trial looks at people having a first psychotic episode who have not yet taken anti-psychotic medicine. It aims to see whether an early support approach can help, before other treatments become necessary.
BronAges 18–35 - NCT01730781Recruiting
PET scan study to image cannabinoid receptors in the brain
This study uses a special brain scan (PET) to measure cannabinoid receptors—areas in the brain that interact with cannabis-like chemicals. It may help researchers better understand how these receptors relate to conditions such as schizophrenia, PTSD, opioid use disorder, or early psychosis risk.
New Haven, ConnecticutAges 18–55 - NCT01409109Recruiting
Study database for brain signal markers in psychosis
This study builds a database of brain-signal measurements to help find “biomarkers” that may point to schizophrenia or related mental illnesses. Depending on whether you have a mental health diagnosis or you’re healthy, the study will collect information and brain data to compare groups.
Dallas, TexasAges 18–60 - NCT01088386Enrolling by invitation
Care program for people receiving Zyprexa Relprevv
This is a study of a patient support program for people already taking Zyprexa Relprevv. It may help by improving how care is managed while you are on this medication.
Blue Bell, PennsylvaniaAges 18 years+
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for schizophrenia?
- Yes. Clin2 currently lists 306 recruiting schizophrenia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a schizophrenia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a schizophrenia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.